This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Daiichi Sankyo Company, Limited, National Cancer Center. Active years: 2020.
Company Filing History:
1 out of 460 
1 out of 263 
Years Active: 2020
Title: The Innovative Contributions of Hideaki Ogiwara
Introduction
Hideaki Ogiwara is a notable inventor based in Chuo-ku, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on the relationship between cancer treatment and specific compounds that inhibit p300, a protein involved in cancer progression.
Latest Patents
Ogiwara holds a patent for a method that predicts responsiveness to cancer treatment using a p300-inhibiting compound. This patent highlights the synthetic lethality relationship between CBP and p300, suggesting that inhibiting p300 is a promising approach for treating CBP-mutated cancers. The therapeutic strategy he developed allows for efficient treatment based on companion diagnostics, enabling the administration of a p300 inhibitor to patients selected based on functional suppression of CBP.
Career Highlights
Throughout his career, Ogiwara has worked with prestigious organizations, including the National Cancer Center and Daiichi Sankyo Company, Limited. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.
Collaborations
Ogiwara has collaborated with notable colleagues, including Yuichi Tominaga and Saito Higuchi. These partnerships have further enriched his research and expanded the impact of his work in the field of oncology.
Conclusion
Hideaki Ogiwara's contributions to cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work not only provides hope for patients with CBP-mutated cancers but also showcases the importance of research and collaboration in the fight against cancer.